Crossmark

Antibody–Drug Conjugates Drug Product Formulation and Process Development, Scalability and Stability Considerations

Crossref DOI link: https://doi.org/10.1208/s12249-026-03457-9

Published Online: 2026-06-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Sorret, Léa https://orcid.org/0009-0007-5138-1041
Ninomiya, Mamiko https://orcid.org/0009-0002-9279-9595
Hillebrandt, Nils https://orcid.org/0000-0002-3097-3140
Schmitt, David https://orcid.org/0009-0002-2431-666X
Chattopadhyay, Arundhati https://orcid.org/0009-0002-4903-7958
McGarvey, Orla https://orcid.org/0009-0001-0746-5973
License Information

Text and Data Mining valid from 2026-06-04

Version of Record valid from 2026-06-04
More Information

Article History

Received: 6 February 2026

Accepted: 8 May 2026

First Online: 4 June 2026

Declarations

:

: All authors are employees of Lonza AG.